CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+18.02%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.06B
AUM Growth
+$1.06B
(-1.1%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-14.08%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
263
Reduced
171
Closed
24
Top Buys
| 1 |
SPDR Gold Trust
GLD
|
$6.59M |
| 2 |
iShares Gold Trust Micro
IAUM
|
$4.62M |
| 3 |
Intuit
INTU
|
$3.73M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
$3.6M |
| 5 |
T-Mobile US
TMUS
|
$2.35M |
Top Sells
| 1 |
Apple
AAPL
|
$17.4M |
| 2 |
NVIDIA
NVDA
|
$12.2M |
| 3 |
Microsoft
MSFT
|
$11.5M |
| 4 |
Amazon
AMZN
|
$8.86M |
| 5 |
Broadcom
AVGO
|
$8.43M |
Sector Composition
| 1 | Technology | 38.15% |
| 2 | Healthcare | 22.68% |
| 3 | Communication Services | 12.64% |
| 4 | Consumer Discretionary | 11.62% |
| 5 | Consumer Staples | 3.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
SPDR S&P Biotech ETF
XBI
$5.27B
| $42.1K | ﹤0.01% |
508
-7,514
| -94% | -$623K |
|
427
Inhibrx
INBX
$405M
| $41.5K | ﹤0.01% |
2,907
+3
| +0.1% | +$43 |
|
428
Y-mAbs Therapeutics
YMAB
$389M
| $41K | ﹤0.01% |
9,097
+113
| +1% | +$510 |
|
429
AC Immune
ACIU
$208M
| $40.9K | ﹤0.01% |
20,167
+330
| +2% | +$670 |
|
430
Codexis
CDXS
$239M
| $40.6K | ﹤0.01% |
16,639
+23
| +0.1% | +$56 |
|
431
scPharmaceuticals
SCPH
$297M
| $40.4K | ﹤0.01% |
10,603
+566
| +6% | +$2.16K |
|
432
Esperion Therapeutics
ESPR
$480M
| $39.2K | ﹤0.01% |
39,808
+286
| +0.7% | +$282 |
|
433
Design Therapeutics
DSGN
$326M
| $38.4K | ﹤0.01% |
11,402
+45
| +0.4% | +$152 |
|
|
CRGX
434
DELISTED
CARGO Therapeutics
CRGX
| $38.2K | ﹤0.01% |
9,262
+30
| +0.3% | +$124 |
|
435
Larimar Therapeutics
LRMR
$341M
| $37.2K | ﹤0.01% |
12,860
+61
| +0.5% | +$176 |
|
436
Editas Medicine
EDIT
$234M
| $37K | ﹤0.01% |
16,813
+255
| +2% | +$561 |
|
437
Omeros
OMER
$295M
| $35.3K | ﹤0.01% |
11,768
+144
| +1% | +$432 |
|
438
Voyager Therapeutics
VYGR
$200M
| $34.6K | ﹤0.01% |
11,114
+157
| +1% | +$488 |
|
439
4D Molecular Therapeutics
FDMT
$287M
| $34.5K | ﹤0.01% |
9,304
+17
| +0.2% | +$63 |
|
440
Enanta Pharmaceuticals
ENTA
$189M
| $32.5K | ﹤0.01% |
4,293
+14
| +0.3% | +$106 |
|
441
Alector
ALEC
$257M
| $28.1K | ﹤0.01% |
20,083
+208
| +1% | +$291 |
|
442
Lexeo Therapeutics
LXEO
$265M
| $26.8K | ﹤0.01% |
6,667
+35
| +0.5% | +$141 |
|
443
Kyverna Therapeutics
KYTX
$160M
| $26.6K | ﹤0.01% |
8,680
+21
| +0.2% | +$64 |
|
444
Vanguard Information Technology ETF
VGT
$98.4B
| $26.5K | ﹤0.01% |
40
+21
| +111% | +$13.9K |
|
445
Lyell Immunopharma
LYEL
$211M
| $26.2K | ﹤0.01% |
2,966
-55,637
| -95% | -$492K |
|
446
Fate Therapeutics
FATE
$122M
| $25.8K | ﹤0.01% |
23,024
+179
| +0.8% | +$200 |
|
447
Align Technology
ALGN
$9.92B
| $25.2K | ﹤0.01% |
133
| – | – |
|
448
Neumora Therapeutics
NMRA
$285M
| $23.8K | ﹤0.01% |
32,486
+80
| +0.2% | +$59 |
|
449
Nkarta
NKTX
$151M
| $23.7K | ﹤0.01% |
14,252
+97
| +0.7% | +$161 |
|
450
Ironwood Pharmaceuticals
IRWD
$214M
| $23.3K | ﹤0.01% |
32,501
+402
| +1% | +$288 |
|